Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
VNDA
Vanda Pharmaceuticals Inc.
NASDAQGM
Biotechnology
United States
$5.43
▲
+0.09 (+1.69%)
CLOSED
—
OPEN
$5.29
HIGH
$5.45
LOW
$5.29
PREV CLOSE
$5.34
VOLUME
589.3K
0.64x avg
BID / ASK
4.37 / 5.78
spr 1.410
MARKET CAP
$328.3M
DAY RANGE
$5.29
$5.45
P/E (TTM)
—
Fwd 27.2
EPS (TTM)
-4.73
DIV YIELD
—
52W HIGH
$9.94
-45.4%
52W LOW
$4.27
+27.2%
BETA
0.65
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$5.45
+0.02
(+0.37%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
VNDA
$5.43
▲
+1.69%
Chart
Valuation
Financials
Peers
News
VNDA · K 線技術分析（即時、可互動）
basic
pro
快速分析（2–5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，一般約 2 分鐘，上游壅塞時最長約 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-ON
252 BARS · +17.8% YOY
1-year price chart. Started at 4.61, currently 5.43, up 17.8 percent. Range 4.32 to 9.56 over 252 data points.
2025-09-05
$4.61 → $5.43 (+17.8%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
—
WACC Used
+7.0%
Terminal g
+3.5%
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers. · Comparables skipped: no peer multiples or no per-share economics from Finnhub metric endpoint.
FINANCIALS
多年財務（SEC XBRL）
CALM
YOY REV +8.7% · 3 FY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
$216.1M
-$220.5M
-$109.4M
-$110.4M
$488.9M
2024-12
$198.8M
-$18.9M
-$15.8M
-$16.2M
$656.2M
2023-12
$192.6M
$2.5M
$12.8M
$12.4M
$648.4M
NEWS
近期新聞（過去 14 天）
CALM
10 HEADLINES · LAST 14 DAYS
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
PR Newswire · 2026-09-02
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
TMX Newsfile · 2026-08-31
Vanda Pharmaceuticals' Skin Disease Drug Gets EU Orphan Drug Designation
MT Newswires · 2026-08-24
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
PR Newswire · 2026-08-24
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
PR Newswire · 2026-08-22
Vanda (VNDA) Q2 2026 Earnings Call Transcript
Motley Fool · 2026-08-12
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Zacks · 2026-08-11
Vanda Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 2026-08-06